Animal Depression Medication Market Size Share Trends Forecast 2026

1. ANIMAL DEPRESSION MEDICATION MARKET ANALYSIS INDUSTRY INSIGHTS, TRENDS, OUTLOOK, AND OPPORTUNITY ANALYSIS, 2020–2027 © Coherent market Insights. All Rights Reserved © Coherent market Insights. All Rights Reserved

2. REPORT DESCRIPTION Animal Depression Medication Market - Overview Increasing pet adoption and growing pet humanization trend driving growth of animal depression medication market in Asia Pacific and Latin America North America is a major region for Animal Depression Medication Market. As per 2015 Pet Secure estimates, the U.S. accounted for the highest dog population of 69,929,000. Animal depression medication market in Asia is growing on account of increasing awareness among the populace regarding animal illness, increasing number of pets, and improving veterinary medical facilities. According to the Pet Asia Fair in 2016, pet adoption in Asia Pacific and Latin America regions is increasing rapidly resulting in increase in demand for nutritional and medicinal products in order to address their growing health concerns. Animal Depression Medication Market Overview Emotions may be described as subjective, conscious experiences characterized by psychophysiological expressions, mental states, and biological reactions. Several tests such as cognitive bias test and leaned helplessness models have been developed to understand feelings of optimism and pessimism in animals. Cognitive biases have been shown in wide range of species, including rats, dogs, cats, sheep, and chicks. Depression in animals can be due to change in routine or change in emotions. Some animals can get depressed when left alone for long hours. Browse Research Reports: https://www.coherentmarketinsights.com/ongoing-insight/animal- depression-medication-market-90 © Coherent market Insights. All Rights Reserved

3. REPORT DESCRIPTION Treatment alternatives for animal depression to boost growth of the animal depression medication market Treatment of animal depression varies according to cause of condition. Blood tests, x-rays, and a physical examination by a veterinarian can help with diagnosis. If the animal has chemical imbalance, then the veterinarian may prescribe anti-depressants or anxiety medication. Paroxetine is an antidepressant used to treat major depressive disorders, social anxiety disorder, and panic disorder. The current standard of treatment of depression involves use of selective serotonin reuptake inhibitors (SSRIs). Depression can be triggered due to lack of serotonin, and SSRIs essentially maintain higher levels of serotonin in the brain to address the issue. It can take up to two months for a drug to be effective in treating depression. Most dogs suffering from such disorders can make a full recovery in six to twelve months after being administered SSRIs. The U.S. Food and Drug Administration has approved only one antidepressant, Clomicalm (clomipramine) for treatment of anxiety in dogs, which would fuel growth of the animal depression medication market. Increasing spending on animal care to boost growth of the animal depression medication market Increasing number of pet animals is a major factor fueling growth of the animal depression medication market. According to 2016 estimates released by Pet Secure, over half of the population in the U.S. owns a cat or a dog. Request a Sample copy of this reports: https://www.coherentmarketinsights.com/insight/request-sample/90 © Coherent market Insights. All Rights Reserved

4. REPORT DESCRIPTION Key players involved in the animal depression medication market Major players in the global animal depression medication market include Torrent Pharmaceuticals Limited, Elite Pharma Private Pharmaceuticals Limited, Cipla Limited, and Eli Lilly and Company. These companies provide drugs that are used to treat depression in animals. Limited, Biomax Laboratories, Intas Key Developments Increasing product approval and launch of animal depression drugs is expected to boost the market growth. For instance, in August 2019, Lupin Limited launched Fluoxetine Tablets USP, 10 mg and 20 mg, a generic version to Eli Lilly and Company’s Proxac tablets. Similarly, in February 2019, Lupin Limited announced the launch of Clomipramine Hydrochloride Capsules USP, a generic version of SpecGx LLC’s Anafranil Capsule, having received an approval from the U.S. Food and Drug Administration (FDA) earlier. Research related to anti-depression drugs is also expected to boost the market. For instance, in July 2019, according to a research published in Lancet Psychiatry, interpretation of depression scale scores may indicate inaccurately that selective serotonin reuptake inhibitors (SSRIs) are not as effective for nonsevere depression. Buy-Now this Research Report @ https://www.coherentmarketinsights.com/insight/buy-now/90 © Coherent market Insights. All Rights Reserved

5. ABOUT COHERENT MARKET INSIGHTS ABOUT US Coherent Market Insights is a global market intelligence and consulting organization focused on assisting its plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, with an office at the global financial capital in the U.S. Our client base includes players from across all business verticals in over 150 countries worldwide. We are uniquely positioned to help businesses around the globe deliver practical and lasting results through various recommendations about operational improvements, technologies, emerging market trends and new working methods. We offer both customized and syndicated market research reports that help our clients create visionary growth plans to provide traction to their business. We meticulously study emerging trends across various industries at both the global and regional levels to identify new opportunities for our clientele. SERVICES CUSTOMIZED RESEARCH INDUSTRY ANALYSIS SYNDICATED RESEARCH COUNTRY SPECIFIC STUDIES MARKET INTELLIGENCE SERVICES CONSULT STUDIES © Coherent market Insights. All Rights Reserved

6. ABOUT CMI SECTOR COVERAGE BIOTECHNOLOGY CLINICAL DIAGNOSTIC HEALTHCARE IT MEDICAL DEVICES MEDICAL IMAGING PHARMACEUTICAL OUR CLIENTS  Global Leading Equipment and System Manufacturers  Marketing Consultancies and the Advertising Industry  Component Providers and System Integrators  Private and Government organization  Distributors, Retailors and Value Added Resellers  Outsourcing Companies  Healthcare IT Solutions Developers  Universities and Business Schools. © Coherent market Insights. All Rights Reserved

7. KEY STATS RESEARCH SOLUTIONS 100+ GLOBAL REPORTS FEASIBILITY STUDIES Insights Published Per Year CUSTOMIZED SOLUTIONS 150+ COUNTRY ANALYSIS Consulting Projects Till Date CONSULT PROJECTS SURVEY RESEARCH 125+ EXCEL FORECAST DATABASE Clients Worldwide Per Year COMPETITIVE ASSESSMENT TECHNOLOGY SNIPPETS 110+ Analysts and Contract Consultants Coherent Market Insights excels at offering unmatched actionable market intelligence across various industry verticals, including chemicals, healthcare, and food & beverages, to name a few. We implement holistic market research methodology in order to result in the best possible market research reports across various industries worldwide. Based on our unmatched expertise across various industries—no matter how large or small, how complex or unique—we help our clients achieve better outcomes with uniquely designed and highly customized solutions. Our coverage includes insights that help our clients ensure sustained growth in developed markets and also key inputs to help them tap into emerging markets and exploit the plethora of opportunities posed therein. © Coherent market Insights. All Rights Reserved

8. THANK YOU To know more about us, visit our website: www.coherentmarketinsights.com For sales queries or new topics email us on: sales@coherentmarketinsights.com For other queries contact: Mr. Shah (Manager - Business Development) Coherent Market Insights sales@coherentmarketinsights.com +1-206-701-6702 © Coherent market Insights. All Rights Reserved